Resistance to first-line anti-TB drugs is associated with reduced nitric oxide susceptibility in Mycobacterium tuberculosis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Idh, Jonna ^a   Mekonnen, Mekidim ^b,c   Abate, Ebba ^a,c,d   Wedajo, Wassihun ^c   Werngren, Jim ^e   Ängeby, Kristian ^f   Lerm, Maria ^a   Elias, Daniel ^g   Sundqvist, Tommy ^a   Aseffa, Abraham ^c   Stendahl, Olle ^a   Schön, Thomas ^h  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^d UNIVERSITY OF GONDAR   (Ethiopia)

^e SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; NITRIC OXIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SENSITIVITY; ETHIOPIA; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; SURVIVAL RATE;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; DRUG RESISTANCE, BACTERIAL; ETHIOPIA; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS; RODENTIA;

EID: 84863090275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039891     Document Type: Article

References (47)

1. Nathan C, Shiloh MU, (2000) Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A 97: 8841-8848.
2. Chan ED, Chan J, Schluger NW, (2001) What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol 25: 606-612.
3. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, et al. (2001) The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 69: 7711-7717.
4. Liu PT, Modlin RL, (2008) Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20: 371-376.
5. Nicholson S, Bonecini-Almeida Mda G, Lapa e SilvaJR, Nathan C, Xie QW, et al. (1996) Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 183: 2293-2302.
6. Rich EA, Torres M, Sada E, Finegan CK, Hamilton BD, et al. (1997) Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber Lung Dis 78: 247-255.
7. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, et al. (1998) 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 66: 5314-5321.
8. Schon T, Elmberger G, Negesse Y, Pando RH, Sundqvist T, et al. (2004) Local production of nitric oxide in patients with tuberculosis. Int J Tuberc Lung Dis 8: 1134-1137.
9. Choi HS, Rai PR, Chu HW, Cool C, Chan ED, (2002) Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med 166: 178-186.
10. Idh J, Westman A, Elias D, Moges F, Getachew A, et al. (2008) Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection. BMC Infect Dis 8: 146.
11. Macallan DC, (1999) Malnutrition in tuberculosis. Diagn Microbiol Infect Dis 34: 153-157.
12. Schon T, Elias D, Moges F, Melese E, Tessema T, et al. (2003) Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur Respir J 21: 483-488.
13. Nathan C, (2008) Microbiology. An antibiotic mimics immunity. Science 322: 1337-1338.
14. Gurumurthy M, Mukherjee T, Dowd CS, Singh R, Niyomrattanakit P, et al. (2012) Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J 279: 113-125.
15. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
16. Manjunatha U, Boshoff HI, Barry CE, (2009) The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2: 215-218.
17. Timmins GS, Master S, Rusnak F, Deretic V, (2004) Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3006-3009.
18. Timmins GS, Deretic V, (2006) Mechanisms of action of isoniazid. Mol Microbiol 62: 1220-1227.
19. Doi T, Ando M, Akaike T, Suga M, Sato K, et al. (1993) Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun 61: 1980-1989.
20. Friedman CR, Quinn GC, Kreiswirth BN, Perlman DC, Salomon N, et al. (1997) Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis 176: 478-484.
21. O'Brien L, Carmichael J, Lowrie DB, Andrew PW, (1994) Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun 62: 5187-5190.
22. Rhoades ER, Orme IM, (1997) Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun 65: 1189-1195.
23. Firmani MA, Riley LW, (2002) Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro. Infect Immun 70: 3965-3968.
24. Inumaru VT, Nogueira PA, Butuem IV, Riley LW, Ferrazoli L, (2009) Reactive nitrogen intermediate susceptibility of Mycobacterium tuberculosis genotypes in an urban setting. Int J Tuberc Lung Dis 13: 665-668.
25. American ST, (1961) National tuberculosis association of the USA diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association.
26. Verdon CP, Burton BA, Prior RL, (1995) Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem 224: 502-508.
27. Schon T, Idh J, Westman A, Elias D, Abate E, et al. (2011) Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis- A randomised trial. Tuberculosis (Edinb) 91: 370-377.
28. Mekonen M, Abate E, Aseffa A, Anagaw B, Elias D, et al. (2010) Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia. Ethiop Med J 48: 203-210.
29. HPA (2003) Standard Operating Procedure: investigation of specimens for mycobacterium species.
30. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, et al. (2002) A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99: 3684-3689.
31. Parsons LM, Brosch R, Cole ST, Somoskovi A, Loder A, et al. (2002) Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J Clin Microbiol 40: 2339-2345.
32. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, et al. (1997) Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
33. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 21-43.
34. NCCLS NCfCLS, (2000) Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes;tentative standard - second edition. NCCLS document M24-T2.
35. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, et al. (2006) Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6: 23.
36. Institut GldP (2011) SITVITWEB. Available: http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/. Accessed 2011 Oct.
37. Demay C, Liens B, Burguiere T, Hill V, Couvin D, et al. (2012) SITVITWEB- A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol 12: 755-766.
38. Jackett PS, Aber VR, Lowrie DB, (1978) Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol 104: 37-45.
39. Keefer LK, Nims RW, Davies KM, Wink DA, (1996) "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 268: 281-293.
40. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, et al. (2007) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51: 2329-2336.
41. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al. (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198: 705-713.
42. Voskuil MI, Bartek IL, Visconti K, Schoolnik GK (2011) The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol 2: 105.
43. Abate G, Hoffner SE, Thomsen VO, Miorner H, (2001) Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 20: 329-333.
44. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, et al. (1996) Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641-1643.
45. Chen L, Xie QW, Nathan C, (1998) Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. Mol Cell 1: 795-805.
46. Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK (1999) AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors 10: 211-217.
47. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.